Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$27.87−1.17 (-4.03%)
Close on Nov 16, 2026Market cap $4.45BP/E –Yield –
Adaptive Biotechnologies cash
Cash and short-term investments held at the end of each period.
Adaptive Biotechnologies's cash was $344.26M at Jun 30, 2026. For fiscal 2025 it was $226.98M, up 2.1% from the year before. The highest annual figure on record is $688.27M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $226.98M | +2.1% |
| FY2024 | Dec 31, 2024 | $222.29M | -35.8% |
| FY2023 | Dec 31, 2023 | $346.40M | -30.5% |
| FY2022 | Dec 31, 2022 | $498.20M | +41.1% |
| FY2021 | Dec 31, 2021 | $353.06M | -48.7% |
| FY2020 | Dec 31, 2020 | $688.27M | +19.3% |
| FY2019 | Dec 31, 2019 | $576.87M | +249.6% |
| FY2018 | Dec 31, 2018 | $165.02M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $344.26M | +74.0% |
| Q1 FY2026 | Mar 31, 2026 | $218.33M | +12.9% |
| Q4 FY2025 | Dec 31, 2025 | $226.98M | +2.1% |
| Q3 FY2025 | Sep 30, 2025 | $212.77M | -12.6% |
| Q2 FY2025 | Jun 30, 2025 | $197.87M | -32.2% |
| Q1 FY2025 | Mar 31, 2025 | $193.42M | -37.4% |
| Q4 FY2024 | Dec 31, 2024 | $222.29M | -35.8% |
| Q3 FY2024 | Sep 30, 2024 | $243.33M | -34.4% |
| Q2 FY2024 | Jun 30, 2024 | $291.88M | -30.0% |
| Q1 FY2024 | Mar 31, 2024 | $308.87M | -29.9% |
| Q4 FY2023 | Dec 31, 2023 | $346.40M | -30.5% |
| Q3 FY2023 | Sep 30, 2023 | $371.13M | -27.0% |
| Q2 FY2023 | Jun 30, 2023 | $417.23M | +8.7% |
| Q1 FY2023 | Mar 31, 2023 | $440.70M | +21.2% |
| Q4 FY2022 | Dec 31, 2022 | $498.20M | +41.1% |
| Q3 FY2022 | Sep 30, 2022 | $508.08M | +22.4% |
| Q2 FY2022 | Jun 30, 2022 | $383.74M | -35.9% |
| Q1 FY2022 | Mar 31, 2022 | $363.56M | -49.1% |
| Q4 FY2021 | Dec 31, 2021 | $353.06M | -48.7% |
| Q3 FY2021 | Sep 30, 2021 | $415.04M | -50.3% |
| Q2 FY2021 | Jun 30, 2021 | $598.41M | +4.9% |
| Q1 FY2021 | Mar 31, 2021 | $714.26M | +28.7% |
| Q4 FY2020 | Dec 31, 2020 | $688.27M | +19.3% |
| Q3 FY2020 | Sep 30, 2020 | $835.08M | +45.6% |
| Q2 FY2020 | Jun 30, 2020 | $570.38M | +34.8% |
| Q1 FY2020 | Mar 31, 2020 | $555.17M | +236.4% |
| Q4 FY2019 | Dec 31, 2019 | $576.87M | – |
| Q3 FY2019 | Sep 30, 2019 | $573.43M | – |
| Q2 FY2019 | Jun 30, 2019 | $423.00M | – |
| Q4 FY2018 | Dec 31, 2018 | $165.02M | – |
See a number that looks wrong?